Halozyme Therapeutics, Inc. (NASDAQ:HALO) increased its revenue guidance for 2022, expecting total revenue to be in the range of $530-560 million, representing 23-26% growth year-over-year. The company’s primary revenue stream is from royalties, which are expected to increase approximately 244% from 2020 and 50% year-over-year to $300 million.

Analysts at Berenberg Bank expect strong growth in royalty revenues to be largely driven by DARZALEX and Phesgo for the near term until the next set of product launches debut in the 2023-25 timeframe, assuming a positive outcome from the Phase III studies, results of which are expected in 2022-23.